Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Daiichi Sankyo’s ADC I-DXd Shows Distinct Safety Profile in SCLC: R&D Head
Daiichi Sankyo said on September 18 that its investigational antibody drug conjugate ifinatamab deruxtecan (I-DXd) demonstrated a safety profile distinct from existing therapies in a PII study in previously treated small cell lung cancer (SCLC). Ken Takeshita, global head of…
To read the full story
Related Article
BUSINESS
- Chugai CEO Says M&A an Option as Strategic Investment Unit Takes Shape
July 28, 2026
- Chugai Forms Strategic Investment Unit to Deepen Innovation Push; Record Japan Filings Eyed
July 27, 2026
- Chugai Notches Strong H1 Growth on Key Products, Roche Exports
July 27, 2026
- Meiji’s Hiyasta Hits PIII Goal in Advanced Melanoma
July 27, 2026
- China First to Approve Takeda’s Oveporexton for Narcolepsy
July 24, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…